Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer | OncLive

Dr. Moul on Challenges With Sequencing Therapies for Prostate Cancer

October 30, 2015

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

Judd W. Moul, MD, urologic oncologist, Duke Medicine, discusses challenges with sequencing therapies for prostate cancer.

The biggest challenge faced, Moul explains, often occurs when a patient has metastatic castration-resistant prostate cancer. Often, Moul starts a treatment plan with sipuleucel-T (Provenge); however, it is unclear whether patients should subsequently receive enzalutamide (Xtandi) or abiraterone acetate (Zytiga).

Both are novel, hormonal therapeutic agents that urologists should be comfortable prescribing to patients. Treatment should be individualized to each patient, Moul adds.


x